AstraZeneca secures Fusion Pharmaceuticals in $2.4bn deal to advance cancer treatment
AstraZeneca has finalized the acquisition of Fusion Pharmaceuticals Inc., a significant move valued at approximately $2.4 billion, designed to enhance its oncology portfolio by incorporating next-generation radioconjugates (RCs) for cancer treatment. This strategic acquisition not only expands AstraZeneca’s capabilities in targeted cancer therapy but also consolidates its research and development footprint in North America. Financial […]
